The E2F-1 promoter has been used to confer tumorselective E1A expression in oncolytic adenoviruses. Tumor specificity is mainly conferred by a unique structure of E2F-responsive sites organized in palindromes. Binding of the E2F-pRb complex to these palindromes results in repression of transcription in normal cells. Owing to deregulation of the Rb/p16 pathway in tumor cells, binding of free E2F activates transcription and initiates an autoactivation loop involving E1A and E4-6/7. ICOVIR-7 is a new oncolytic adenovirus designed to increase the E2F dependency of E1A gene expression. It incorporates additional palindromes of E2F-responsive sites in an insulated E2F-1 promoter controlling E1A-D24. The E2F palindromes inhibited replication in normal cells, resulting in a low systemic toxicity at high doses in immunocompetent mice. The D24 deletion avoids a loop of E2F-mediated selfactivation in nontumor cells. Importantly, the additional E2F-binding hairpins boost the positive feedback loop on the basis of E1A-mediated transcriptional regulation of E4-6/7 turned on in cancer cells and increased antitumoral potency as shown in murine subcutaneous xenograft models treated by intravenous injection. These results suggest that the unique genetic combination featured in ICOVIR-7 may be promising for treating disseminated neoplasias.
Introduction
Genetic engineering techniques and a better understanding of the interactions between viruses and cells result in an improved design of tumor-selective adenoviruses for cancer treatment. 1 Among the modifications introduced into oncolytic adenoviruses to confer tumor selectivity, promoters for E1A transcription control are essential if systemic use is desired, as they can prevent E1A expression in nontarget tissues. In this regard, tissue-specific promoters have been tested to target cancers arising from specific tissues. 2, 3 However, promoters active in a wider range of tumor types increase the patient population potentially benefiting from a new treatment agent. A tight and potent promoter regulated by repression in normal cells and activation in tumor cells might be an ideal option for reaching a high antitumor effect with low toxicity.
Deregulation of the retinoblastoma (Rb/p16) pathway is a hallmark of cancer cells. 4 Aberrations of this pathway lead to the release of E2F transcription factors for the activation of the E2F site containing promoters. Most E2F-responsive genes are involved in the control of cell cycle or in DNA synthesis and its activation leads to an S-phase entry. It is interesting that silencing of these promoters is also carried out by the same E2F-binding sites in quiescent cells, when E2F is bound to pRb. The formation of a complex involving E2F-pRb and histone deacetylase represses transcription by binding to E2F sites. 5 One of the promoters controlled by E2F is the E2F-1 promoter. It is subject to a strict activation loop of transcription because of its unique roles in apoptosis and DNA repair. 6 Transcriptional control of this promoter depends on a unique structure consisting in four E2F-binding sites organized as two imperfect palindromes. 7, 8 Importantly, a similar palindromic pattern controls the expression of the E2a promoter of adenovirus type 5, 9 suggesting the optimal structure of this arrangement in terms of DNA length to confer E2F responsiveness.
S-phase induction is a requisite for adenoviral life cycle. Therefore, adenoviruses have evolved two different mechanisms to induce an expression of the E2F-1 gene. First, the E1A protein displaces pRb from the E2F-pRb complex to release E2F and activate E2F-1 and viral promoters. 10 Second, the E4-6/7 protein complements this function by binding to free E2F and forming a complex that induces the cooperative and stable binding of E2F to the inverted binding sites present in the E2F-1 and E2a promoter. 11 Disruption of the Rb pathway in tumor cells can functionally substitute E1A-mediated E2F release and, therefore, selective replication in tumor cells can be achieved by deleting the pRb-binding site of E1A. This has been used in D24 and dl922-947 oncolytic adenoviruses. 12, 13 However, a constitutive expression of mutated E1A protein in every infected cell causes high toxicity by itself and compromises the systemic administration of these viruses for treatment of disseminated cancer. With the aim of overcoming this limitation, the E2F-1 promoter has been used to control E1A transcription because of its E2F addiction. 14 In normal cells, binding of the E2F-pRb complex to the promoter restricts E1A transcription and the viral life cycle is aborted. In cancer cells, E1A transcription is activated by free E2F and a loop of autoactivation is triggered by E1A and E4-6/7, leading to the replication of the virus and lysis of cancer cells.
In this study, we modify the E2F-1 promoter to increase the dependency of virus replication on free E2F. Our group has previously described ICOVIR-5, an oncolytic adenovirus controlling selective replication at different levels: transduction (integrin-mediated adenoviral infection), transcription (insulated E2F-1 promoter, which contains two palindromic E2F-responsive sites, controlling E1A), optimized ribosome recognition (Kozak sequence) and protein-protein interaction (E1A-D24 unable to bind pRb). ICOVIR-5 has shown a potent antiglioma effect alone 15 or in combination with chemotherapy 16 and antitumor efficacy in a wide range of subcutaneous tumor models after systemic administration with a low toxicity profile. 17 In this study, we improved the transcriptional control of E1A using an E2F-1 promoter modified by the insertion of four extra E2F-palindrome sites. Viral replication is improved in cancer cells and an important enhancement of antitumoral potency in vivo is achieved in all cancer models tested. Importantly, replication in normal cells and toxicity in mice are not compromised by this promoter modification. These results are potentially applicable to improve the selectivity and potency of other oncolytic adenoviruses currently based on promoters controlled by E2F transcription factors or even on promoters without E2F sites.
Results

ICOVIR-7 replication is restricted in normal cells
The palindromic E2F-binding sites located between positions À36 and À6 of the E2F-1 promoter confer the potency and selectivity of this promoter. 7, 8 ICOVIR-5 is an oncolytic adenovirus controlling E1A-D24 transcription under the E2F-1 promoter. [15] [16] [17] To enhance the dual role of E2F on transcription control, an E2F-responsive promoter was constructed by inserting four new E2F-responsive palindromes into the E2F-1 promoter. ICOV-IR-7 is a novel oncolytic adenovirus designed to increase selective replication in tumor cells by placing this modified E2F-responsive promoter to control E1A-D24 transcription. As E1A expression determines toxicity, 18 a stricter control of E1A transcription may allow the systemic administration of oncolytic adenoviruses for the treatment of disseminated neoplasias. Figure 1a represents how genetic modifications of ICOVIR-7 work together to abrogate replication in normal cells.
Treatment of disseminated cancer requires a systemic injection of the oncolytic agent. As a large proportion of the virus administered systemically ends up in the liver, analysis of virus replication in precision-cut human liver slices is an important tool for estimating liver toxicity. 19 Liver biopsy samples were infected and cell extracts were titrated at day 6 after infection. We reached a complete inhibition of replication with ICOVIR-7, detecting the same progeny production as with the nonreplicative negative control AdTL-RGD (Figure 1b ). Replication inhibition with ICOVIR-5 was also complete. Another tissue type relevant in adenoviral toxicity is endothelium. Vascular endothelium injury is reported to be a prominent abnormality after a high-dose injection of adenovirus. 20 Human umbilical vein endothelial cells (HUVECs) were infected and replication after 4 days was analyzed. It was of interest that ICOVIR-7 replicated almost sevenfold less than AdwtRGD and was even more selective than ICOVIR-5, reducing by twofold the replication of this previous version (Figure 1c , Po0.05).
Hepatic and hematological toxicity after systemic ICOVIR-7 administration in vivo To assess in vivo systemic toxicity after ICOVIR-7 administration, immunocompetent mice were injected with increasing doses of ICOVIR-7 or control viruses by a single intravenous injection. Animals were weighed daily and liver enzymes (AST and ALT) and hematological parameters were determined at day 5 after injection. For positive control AdwtRGD, samples were collected at day 3 after injection because of much higher toxicity. No casualties were observed after administration of ICOVIRs.
Transaminase elevation is an indicator of liver injury after systemic administration of adenoviruses, 21 and it has been reported after a high-dose injection of oncolytic adenovirus in clinical trials. 22, 23 A dose of 5 Â 10 10 viral particles of AdwtRGD caused up to an 80-fold elevation of both AST and ALT compared with non-treated animals ( Figure 2a ). In contrast, the injection of the same dose of ICOVIR-7 did not increase transaminase levels significantly. Even at a higher dose of ICOVIR-7 (1 Â 10 11 viral particles per mouse), only a slight increase in transaminase levels was observed. Hematological alterations are also frequently observed after systemic administration of large doses of adenoviruses. 20, 23, 24 We observed significant thrombocytopenia and lymphopenia after AdwtRGD injection, but not after ICOVIR-7 (Figures 2b  and c) . In addition, although intravenous AdwtRGD at 5 Â 10 10 viral particles decreased the body weight of mice significantly, indicating high toxicity, ICOVIR-7 at the same dose did not differ from phosphate-buffered saline (PBS) in this regard (Figure 2d ). A dose of 1 Â 10 11 viral particles of ICOVIR-5 or ICOVIR-7 per mouse slightly reduced the body weight of mice.
Owing to the inability of human adenoviruses to productively replicate in mouse cells, the main toxicity in murine livers is associated with E1A expression. 18 Strong immunostaining was detected throughout livers from AdwtRGD-treated mice. In contrast, even at the highest dose of ICOVIR-7 (1 Â 10 11 viral particles per mouse), little E1A was detected, indicating that the E2F-responsive promoter effectively restricts the expression of E1A in liver (Figure 3a) . A histological analysis of livers from animals treated with AdwtRGD revealed evident symptoms of degenerative cirrhosis (macrosteatosis, presence of Councilman bodies and large necrotic areas), symptoms that were absent in livers from ICOVIR-7-treated animals ( Figure 3b) . Importantly, the in vivo toxicity Improved E2F promoter for oncolytic application JJ Rojas et al profile of ICOVIR-7 was similar to that of ICOVIR-5, which is a highly selective virus, but also somewhat abrogated in terms of potency in tumor cells.
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The E2F-binding hairpins in ICOVIR-7 rescue oncolytic potency in vitro E2F-responsive sites have a double role in controlling transcription. 5 Besides repressing transcription when E2F is bound to pRb, they also activate transcription when E2F is released, as occurs in cancer cells. Figure 4a depicts the manner in which new E2F-responsive palindromes introduced in the ICOVIR-7 E1A-D24-controlling promoter cooperate with the E4-6/7 protein to activate replication and overcome the attenuation that ICOVIR-5 presents in some cancer cell lines. To test oncolytic potency in vitro, a panel of tumor cell lines, including lung, cervix, prostate, colon, head and neck carcinoma, melanoma and osteosarcoma, was infected. E1A expression 20 h after infection and virus production 4 days after infection were analyzed for ICOVIR-7 and control viruses.
E1A is the first gene expressed from the adenovirus genome and controls the expression of other virus genes. 25, 26 The enhancement of its selective expression in tumor cells may result in an increase of oncolytic potency. In this regard, ICOVIR-7 was able to restore E1A levels similar to AdwtRGD on all tested cancer cell lines, as analyzed by western blot (Figure 4b ). A densitometric quantification of E1A bands revealed an increase in E1A levels by 17% in A549, by 152% in Saos-2, by 119% in 1.36.1.5 and by 254% in SCC-25 cells with respect to ICOVIR-5. It is significant that this restoration of expression was more evident in the cancer cell lines in which the E1A expression of ICOVIR-5-infected cells was reduced (Saos-2, 1.36.1.5 and SCC-25). A near wild-type level of E1A expression is important to maintain an efficient virus replication. 27 ICOVIR-5 progeny production was attenuated in some cancer cell lines and ICOVIR-7 was able to increase its replication in most of them, namely, in Saos-2, Sk-mel28, 1.36.1.5, C33A and Isrec-01 ( Figure 4c ). Significantly, this improvement was most apparent in Saos-2 and Sk-mel28, in which ICOVIR-5 replication was weakened compared with that of AdwtRGD. In addition, cytopathic effect assays were carried out to determine IC 50 in different tumor cell lines. The amount of ICOVIR-7 needed to kill 50% of cells was lower in all tumor cell lines tested (Supplementary Table 1 ). These data indicate that the insertion of ICOVIR-7 incorporates four extra palindromes of E2F-responsive sites in the E2F-responsive promoter controlling E1A-D24. In quiescent cells, the E2F transcription factor forms a complex with functional pRb. The binding of the complex to these hairpins of E2F-responsive sites avoids E1A-D24 transcription by the docking of histone deacetylase to the complex. The D24-deleted E1A cannot disrupt the pRb-E2F complex, which prevents a vicious circle of autoactivation by E2F in case of promoter leakage. Furthermore, the DM-1 insulator avoids selectivity loss by the endogenous E1A enhancer. (b) Viral replication in human liver slices. Human liver slices were infected at 50 transduction units per cell (TU per cell) and viral yield (TU per slice) was determined in slice extracts at day 6 after infection. AdTL-RGD is a replication-deficient control, AdwtRGD is a nonselective positive control, whereas ICOVIR-5 is an older oncolytic virus featuring a prototype E2F-1 promoter for controlling E1A-D24 transcription. (c) Viral replication in normal human umbilical vein endothelial cells (HUVECs). HUVECs were infected with a nonreplicative virus (AdTL-RGD), with AdwtRGD, ICOVIR-5 or ICOVIR-7 at a multiplicity of infection of 40 and virus production was measured in cell extracts 5 days after infection as indicated in Materials and methods. The means of four independent replicas are shown and two independent experiments were carried out. +s.d. error bars are plotted. y Significant Po0.05 by two-tailed unpaired Student's t-test, compared with that of the AdwtRGD-infected group. *Significant Po0.05 by two-tailed unpaired Student's t-test, compared with that of the ICOVIR-5-infected group.
Improved E2F promoter for oncolytic application JJ Rojas et al additional E2F-responsive sites in E1A-controlling promoter results in improved oncolytic potency in vitro and may involve a more efficient antitumor treatment in vivo.
Antitumor efficacy of ICOVIR-7 after systemic administration
Subcutaneous models were selected to represent a wide range of tumor types. As disseminated disease is the most relevant clinical situation, mice bearing C33A (cervix), Sk-mel28 (melanoma), NP-18 (pancreatic adenocarcinoma) or PC-3 (prostate) tumors were injected with a single intravenous dose of ICOVIR-7, ICOVIR-5 or PBS. AdwtRGD could not be tested in these experiments because of its high toxicity at treatment doses, as shown in Figure 2 .
When animals with C33A tumors were treated with PBS, tumor size at day 32 was 7.3-fold larger than in mice Figure 2 In vivo toxicity profile of ICOVIR-7. Body weight variation (a) and serum transaminase (b), platelet (c) and lymphocyte (d) concentrations in Balb/C mouse peripheral blood at day 5 after intravenous administration of phosphate-buffered saline (PBS) or ICOVIRs; the AdwtRGD-injected group was analyzed at day 3 after administration because this dose represented more than the LD 50 at day 4 and it was analyzed only at the lower dose because it is lethal at day 3 after administration with the higher dose.
y Significant Po0.05 by two-tailed unpaired Student's t-test, compared with that of the AdwtRGD group. # Significant Po0.05 by two-tailed unpaired Student's t-test, compared with that of the PBS group.
Improved E2F promoter for oncolytic application JJ Rojas et al treated with ICOVIR-7 (Po0.05) (Figure 5a ). Furthermore, ICOVIR-7 seemed more effective than ICOVIR-5, as tumor size was 1.75-fold larger in the latter group (not significant). In mice with Sk-mel28 tumors, tumor size in PBS-treated mice was 2.6-fold higher than in the ICOVIR-7 group (Po0.0009) (Figure 5b ). Moreover, tumors in mice treated with ICOVIR-5 were 1.7-fold larger than those in mice treated with ICOVIR-7 (Po0.05). In mice bearing NP-18 tumors, an aggressive model of pancreatic adenocarcinoma, tumor size in PBStreated animals was twofold larger than that in the ICOVIR-7 group (Po0.00002) (Figure 5c ). Tumors treated with ICOVIR-5 at the end of the experiment were 1.5-fold larger than those treated with ICOVIR-7 (Po0.01). In mice with PC-3 xenografts, a single intravenous treatment was not as effective as in the other two models perhaps because of higher amounts of hyaluronic acid and other matrix components. 28, 29 However, tumors in PBS-treated animals were nevertheless 1.7-fold larger than in ICOVIR-7-treated animals (Po0.05) (Figure 5d ) and tumors in ICOVIR-5-treated animals were 1.2-fold bigger than those in the ICOVIR-7 group (not significant).
Viral replication in tumors after systemic injection of ICOVIR-7 was shown by immunohistofluorescence for adenoviral capsid proteins. Tumors were collected at day 25 after injection. No capsid proteins were observed in untreated tumors, whereas positive cells were observed in ICOVIR-7-treated tumors (Figure 5e ).
Discussion
Treating tumors at an advanced stage requires systemic delivery. Clinical data with oncolytic adenoviruses injected systemically indicate the need for more potent and selective viruses. Those tested in patients have proven to be relatively safe, showing evidence of efficacy. 22, [30] [31] [32] However, some potentially concerning adverse effects were observed at high doses and most responses detected were transient, suggesting the need for enhancing efficacy. Therefore, further research is required to improve selectivity and, above all, potency of these viruses.
Tumors cells are characterized by presenting defects in the Rb pathway, which inhibit pRb binding to E2F. 4 An oncolytic adenovirus that takes advantage of this deregulation may acquire a selective replication for tumor cells. The first modification aiming conditional replication in Rb pathway-deficient cells was the D24 (dl922-947) deletion. 12, 13 This modification consists of deleting the pRb-binding site of the conserved region 2 (CR2) of E1A proteins. E1A proteins, besides being the first viral proteins synthesized from the adenovirus genome and capable of activating the transcription of other virus genes, activate the cell cycle through binding to the pRb, p130 and p107 family of proteins. 33 The formation of this complex releases E2F from pRb to allow the transcription activation of viral and cellular genes containing E2F-responsive sites. As the Rb pathway is dysfunctional in virtually all tumor cells, 4 E1A binding to pRb is not necessary in malignant cells. Therefore, D24 deletion results in attenuated replication in normal cells while preserving oncolytic potency. Furthermore, a virus combining this deletion with the insertion of an RGD motif at the HI loop of the fiber has shown improved oncolytic potency. 34 Despite this inability to release E2F, hepatic toxicity is observed when this virus is injected systemically, as E1A transcription is not regulated and takes place in normal cells. 18 For the systemic treatment of disseminated cancer, E1A transcription control is required. In this regard, the E2F-1 promoter has previously been used to direct E1A transcription in response to Rb pathway deregulation. [35] [36] [37] Among Figure 3 ICOVIR-7 retains the high selectivity of ICOVIR-5 with regard to hepatic toxicity and expression of E1A in vivo. Liver E1A expression was assessed by immunohistofluorescence in frozen sections (a) and hematoxylin-eosin staining of equivalent paraffin-embedded liver sections was performed (b). Mouse livers were collected at day 3 after intravenous administration of phosphate-buffered saline or viruses. Livers from mice injected with ICOVIR-5 or ICOVIR-7 at both doses were close to negative for E1A expression and hepatic toxicity, whereas livers from mice injected at 5 Â 10 10 viral particles (vp) present intense E1A expression and evident signs of hepatitis, such as macrosteatosis, for the presence of Councilman bodies and large necrotic areas.
Improved E2F promoter for oncolytic application JJ Rojas et al several cellular E2F-responsive promoters, E2F-1 is a popular choice because of its efficient E2F-binding structure, which consists of four binding sites organized as two imperfect palindromes. 7, 8 Besides the E2F release by E1A, the adenoviral E4-6/7 protein has also evolved to increase free E2F levels. This protein interacts directly with different members of the E2F family and mediates the stable binding and activation of the E2F-1 promoter. 11 As a result, we reach an efficient and important positive feedback loop in tumor cells when this promoter is Improved E2F promoter for oncolytic application JJ Rojas et al placed to control E1A transcription. Furthermore, the loop is increased by the presence of a similar E2F-binding structure in the E2a promoter of adenovirus 5. 38 Previously, our group has shown the importance of combining D24 deletion with an insulated E2F-1 promoter that controls E1A transcription as a safety measure in case of promoter leakage. 27 The binding of zinc-finger protein CTCF to the insulator DM-1 prevents transcription from E1A enhancers and the D24 deletion abrogates a feedback loop in normal cells. Furthermore, we also showed that oncolytic potency can be enhanced by using the optimal ribosome recognition sequence upstream of E1A. 17 Taking into consideration the sophisticated cooperation of E1A-D24 and E4-6/7 with the unique structure of E2F sites present in E2F-1 promoter to activate/repress replication, we decided to magnify this mechanism by multiplying the number of these unique structures in the E1A-controlling promoter. Thus, ICOVIR-7 incorporates eight new E2F-binding sites organized as four palindromes in addition to the endogenous ones present in the wild-type E2F-1 promoter. The new sites were inserted upstream of CAAT boxes to avoid interfering on transcription initiation. As a result, higher levels of free E2F binding may increase E1A transcription in cancer cells. This may lead to a higher activation of viral promoters, resulting in higher levels of the E4-6/7 protein and activating a potent loop of E1A and E2a production that may culminate in a more efficient production of virus in cancer cells. Our results corrobo- Improved E2F promoter for oncolytic application JJ Rojas et al rate this hypothesis. E1A production was enhanced in all cancer lines tested ( Figure 4b ) and this had a positive effect on virus production, increasing the number of virions produced by most of the tumor cell lines tested (Figure 4c ). Importantly, this enhancement was maintained when viruses were tested in subcutaneous mouse models. A substantial benefit in the control of tumor growth was observed after a systemic injection of ICOVIR-7 compared with ICOVIR-5 (Figures 5a-d) . Therefore, our data suggest that high levels of E1A are important to maintain oncolytic potency in all tumor cell models, contrary to some reports in which reduced E1A expression had little effect on replication. 39, 40 Theoretically, the new E2F-binding sites may attach a higher number of E2F-pRb-histone deacetylase complexes in normal cells and this may strengthen the association of nucleosomes with DNA, increasing transcription repression. 5 However, our results indicate that selectivities of ICOVIR-5 and ICOVIR-7 are similar. Liver (Figures 1b, 2a and 3 ) and hematological toxicity (Figures 2b and c) is not reduced by this promoter modification. This is probably because of the fact that the genetic combination present in ICOVIR-5 already efficiently restricts replication in normal cells when injected systemically, showing selectivity levels difficult to improve. This is clearly observed in Figure 1b , in which replication of both ICOVIRs in liver slices was similar to that of a nonreplicating virus (AdTL-RGD), indicating the detection of remaining viruses and discarding replication in that model. After the administration of adenoviruses, there is an induction of two distinct peaks of inflammatory response occurring at 6 h and 5 days. 41 The early phase is capsid mediated and the second peak is dependent on the transcription of viral proteins. The low levels of E1A expression in the liver driven by both ICOVIRs (Figure 1a ) and previous toxicity experiments injecting 1 Â 10 11 UV-psoralen-inactivated viral particles (data not shown) suggest that the transaminase elevation and the slight loss of weight observed after injection of 1 Â 10 11 viral particles of ICOVIRs are probably because of the toxicity caused by adenoviral capsids, not by E1A. In addition, replication in HUVECs (Figure 1c) shows an advantage of ICOVIR-7 in terms of selectivity, but cultured cells arrested by serum deprivation are less reliable as a normal cell model because of the difficulty to be completely arrested. In fact, we detected proliferation markers (cyclin E and Ki-67) in HUVECs or in human hepatocyte extracts by western blot analysis (data not shown), even after serum deprivation. This proliferating status might explain the small difference in terms of replication in HUVECs between wild-type virus and ICOVIRs. Importantly, western blot analysis did not reveal detection for proliferation markers in human liver slice extracts. Thus, we can conclude that the genetic combination present in the ICOVIR backbone properly controls E1A-mediated toxicity.
Despite the potential enhancement of antitumor potency, complete regression of tumors was not achieved in mice models. Tumor masses, besides cancer cells, are composed of stromal areas, including fibroblasts, endothelial and immune cells and matrix components such as collagen or hyaluronan acid. Many tumor types are characterized by small groups of tumor cells surrounded by large areas of stroma and this may limit the intratumoral spread of viruses, especially when replication is restricted to cancer cells. 42, 43 Figure 5d shows how the use of a xenograft model (PC-3) expressing high amounts of matrix components 28, 29 reduces the efficacy of ICOVIR-7 with respect to other models. Arming adenoviruses with therapeutic transgenes is a rational approach to circumvent these barriers. The coadministration of soluble hyaluronidase with oncolytic adenoviruses 44 or the expression of relaxin in the context of an oncolytic adenovirus 45 seems promising. Alternatively, the use of prodrug-converting enzymes may represent a useful tool to breach endothelial and fibroblastic cell barriers. [46] [47] [48] Thus, incorporation of different transgenes into the ICOVIR-7 backbone is under consideration. Restriction of the expression of these transgenes in normal cells and their compatibility with the viral life cycle are important issues to be considered. Late expression has been postulated as a good solution to avoid such problems, as major late promoter transcription is subjugated to E1A expression. 49 The tight control of E1A exerted by the ICOVIR-7 backbone implies that incorporation of a transgene expressed late in the viral cycle may contribute to tumor eradication without increasing toxicity in normal cells.
In summary, our data point toward ICOVIR-7 being a potent oncolytic agent against a broad range of tumors that present limited toxicity when injected systemically. However, further research needs to be carried out to achieve total tumor regression with a single intravenous adenovirus dose.
Materials and methods
Cell culture
HEK293 (human embryonic kidney cells), A549 (human lung adenocarcinoma), SkMel-28 (melanoma), SCC-25 (head and neck squamous carcinoma), Saos-2 (osteosarcoma) and C33A (cervix carcinoma) cell lines were obtained from American Type Culture Collection (Manassas, VA, USA). NP-18 (pancreatic adenocarcinoma) was obtained from our laboratory. 50 The 1.36.1.5 (a clone of SkMel-131, melanoma) cell line was a kind gift from FX Real (Institut Municipal d'Investigació Mèdica, Barcelona, Spain). Isrec-01 (colon cancer cell line) was a kind gift from R Iggo (University of St Andrews, Scotland, UK). HUVECs (human umbilical vein endothelial cells) were purchased from Cambrex Bio Science Baltimore Inc. (Baltimore, MD, USA). All tumor cell lines, excluding Isrec-01, were maintained in Dulbecco's modified Eagle's medium (DMEM) containing 5% fetal bovine serum at 37 1C, 5% CO 2 . The DMEM of Isrec-01 cells was supplemented with 10% fetal bovine serum. HUVECs were cultured in endothelial cell medium.
Viruses
AdwtRGD, AdTL-RGD and ICOVIR-5 have been previously described. 17, 51, 52 All these viruses were propagated in A549 cells, excluding the replication-deficient AdTL-RGD, which was propagated in HEK293 cells. ICOVIR-7 was created by inserting two E2F-binding site hairpins in the E2F-1 promoter of ICOVIR-5. To this aim, a unique BsiWI site was created in the E2F-1 promoter of pGEM-E2F-K-E1A-D24 by site-directed mutagenesis. Using this plasmid digested with BsiWI and oligonucleoImproved E2F promoter for oncolytic application JJ Rojas et al tides E2FF2 (5 0 -GTACGTCGGCGGCTCGTGGCTCTTT CGCGCAAAAAGGATTTGGCGCGTAAAAGTGGTTCGA A-3 0 ) and E2FR2 (5 0 -GTACTTCGAACCACTTTTACGCG CCAAATCCTTTTTGCCGCGAAAGAGCCACGAGCCG CCGAC-3 0 ) annealed, pGEM-E2F3-K-E1A-D24 was created. The KpnI fragment containing the modified version of the E2F-1 promoter was inserted into pShuttle-DM-E2F-K-E1A-D24 to generate pShuttle-DM-E2F3-K-E1A-D24. Finally, this plasmid was recombined with pVK503 by homologous recombination in Escherichia coli BJ to construct pICOVIR-7. ICOVIR-7 was obtained by transfection of the PacI fragment of pICOVIR-7 in HEK293 cells. The virus was plaque purified, amplified in A549 cells and purified using a CsCl gradient. The viral genome was verified by restriction analysis and by sequencing the DM-1 insulator, E2F-1 promoter, Kozak sequence, E1A-D24 and RGD-modified fiber using oligonucleotides oligo22 (5
Human liver slice preparation
Human liver samples were obtained from the Department of Surgery of the Hospital Universitari de Bellvitge (L'Hospitalet de Llobregat, Spain), with approval from the Research Ethics Committee. Liver slices were prepared using a Krumdieck Tissue Slicer (Alabama R&D, Munford, AL, USA) as described. 53, 19 The slices were washed and incubated for 2 h before infection at 37 1C with Williams' E medium saturated with 95% O 2 / 5% CO 2 and supplemented with 10% fetal bovine serum, insulin (0.1 mM) and D-glucose (25 mM).
E1A protein expression analysis
Cell cultures (B2 Â 10 5 cells seeded in 6-well plates) were infected at a multiplicity of infection that allowed at least 80% infectivity (multiplicity of infection (MOI) of 40 for SCC25 cells, MOI of 20 for 1.36.1.5 and Saos-2 cells and MOI of 10 for A549 cells). Whole-cell protein extracts were prepared 24 h after infection by incubation in lysis buffer (400 mM NaCl, 1 mM EDTA, 5 mM NaF, 10% glycerol, 1 mM sodium orthovanadate, 0.5% Nonidet NP-40 and a mixture of protease inhibitors (Sigma, St Louis, MO, USA) in 10 mM Tris-HCl pH 7.4) for 1 h at 4 1C. Clarified samples (15 mg per lane) were separated by a 10% SDS polyacrylamide gel electrophoresis and were transferred to a nitrocellulose membrane (GE Healthcare, Arlington Heights, IL, USA). Detection was carried out by immunoblotting membranes using a polyclonal anti-E1A primary antibody (Rabbit, Clone 13S-5) (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and a polyclonal anti-rabbit conjugated with horseradish peroxidase (goat, DakoCytomation, Glostrup, Denmark). E1A bands from western blot were quantified using a BIO-RAD GS-800 densitometer (Bio-Rad, Hercules, CA, USA).
Virus progeny production
Cell cultures (B2 Â 10 5 cells seeded in 6-well plates) were infected at an MOI that allowed at least 80% infectivity (MOI of 40 for SCC25 and HUVECs, MOI of 20 for Skmel28, PC-3, Isrec-01, 1.36.1.5 and Saos-2 cells and MOI of 10 for C33A and A549 cells). Human liver slices were infected at an MOI of 50, with an estimated cell number of 1 Â 10 6 cells per slice on the basis of a 10-cell-thick slice (B250 mm) and an 8-mm-slice diameter. 19 At 2 h after infection, cultures were washed twice and incubated in a fresh virus-free medium. At day 4 after infection for cell cultures or at day 6 for human liver slices, cells and medium were harvested together and freeze thawed thrice. Viral titers were determined by an antihexon staining-based method. 27 In vivo toxicity study Mice for toxicological and efficacy studies were maintained in the facility of the Institut de Recerca Oncolò -gica-IDIBELL (Barcelona), AAALAC unit 1155. All animal studies were approved by the Institut d'Investigacio Biomedica de Bellvitge Ethical Committee for Animal Experimentation. Purified viral particles (5 Â 10 10 or 1 Â 10
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) were injected intravenously into the tail vein of 6-week-old immunocompetent Balb/C male mice in a volume of 10 ml kg À1 in PBS (n ¼ 5). Daily observations for body weight, morbidity and moribundity were carried out. At day 3 after injection for AdwtRGD-injected mice and at day 5 after injection for ICOVIRs-and PBS-treated animals, the mice were killed and different samples were collected. Blood samples were collected by intracardiac punction, and clinical biochemical and hematological determinations were carried out by the Clinical Biochemistry and Hematological Services of the Veterinary Faculty at the Autonomous University of Barcelona. The significance of differences in biochemical and hematological rates between treatment groups was assessed by a two-tailed Student's unpaired t-test. Mice livers were resected and portions were fixed in 4% formaldehyde for 24 h at room temperature (for paraffin embedding and further hematoxylin-eosin staining) or frozen in OCT. E1A-immunodetection was performed by incubating OCT-embedded liver sections with a primary polyclonal antibody antiadenovirus-2 E1A (clone 13 S-5, Santa Cruz Biotechnology) and an AlexaFluor 488-labeled goat anti-rabbit antibody (Molecular Probes, Eugene, OR, USA). Slides were counterstained with 4 0 ,6-diamino-2-phenylindole and visualized under a fluorescent microscope (Olympus BX51, Hamburg, Germany).
In vivo antitumoral efficacy
Subcutaneous C33A cervical, SkMel-28 melanoma, NP-18 pancreatic adenocarcinoma or PC-3 prostate carcinoma tumors were infused by injection of 1 Â 10 7 cells into the flanks of 6-week-old male Balb/C nu/nu mice. When tumors reached 100 mm 3 (experimental day 0), mice were randomized (n ¼ 10-16 per group) and were injected by a single intravenous injection of PBS, with 
